Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease

Bertalan Mesko, Szilard Poliska, Andrea Váncsa, Zoltan Szekanecz, Karoly Palatka, Zsolt Hollo, Attila Horvath, Laszlo Steiner, Gabor Zahuczky, Janos Podani, Laszlo Nagy

Research output: Contribution to journalArticle

Abstract

Background: Biological therapies have been introduced for the treatment of chronic inflammatory diseases including rheumatoid arthritis (RA) and Crohn's disease (CD). The efficacy of biologics differs from patient to patient. Moreover these therapies are rather expensive, therefore treatment of primary non-responders should be avoided.Method: We addressed this issue by combining gene expression profiling and biostatistical approaches. We performed peripheral blood global gene expression profiling in order to filter the genome for target genes in cohorts of 20 CD and 19 RA patients. Then RT-quantitative PCR validation was performed, followed by multivariate analyses of genes in independent cohorts of 20 CD and 15 RA patients, in order to identify sets ofinterrelated genes that can separate responders from non-responders to the humanized chimeric anti-TNFalpha antibody infliximab at baseline.Results: Gene panels separating responders from non-responders were identified using leave-one-out cross-validation test, and a pool of genes that should be tested on larger cohorts was created in both conditions.Conclusions: Our data show that peripheral blood gene expression profiles are suitable for determining gene panels with high discriminatory power to differentiate responders from non-responders in infliximab therapy at baseline in CD and RA, which could be cross-validated successfully. Biostatistical analysis of peripheral blood gene expression data leads to the identification of gene panels that can help predict responsiveness of therapy and support the clinical decision-making process.

Original languageEnglish (US)
Article number59
JournalGenome Medicine
Volume5
Issue number6
DOIs
StatePublished - Jun 28 2013
Externally publishedYes

Fingerprint

Crohn Disease
Rheumatoid Arthritis
Genes
Gene Expression Profiling
Therapeutics
Gene Pool
Biological Therapy
Biological Products
Transcriptome
Infliximab
Anti-Idiotypic Antibodies
Chronic Disease
Multivariate Analysis
Tumor Necrosis Factor-alpha
Genome
Gene Expression
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. / Mesko, Bertalan; Poliska, Szilard; Váncsa, Andrea; Szekanecz, Zoltan; Palatka, Karoly; Hollo, Zsolt; Horvath, Attila; Steiner, Laszlo; Zahuczky, Gabor; Podani, Janos; Nagy, Laszlo.

In: Genome Medicine, Vol. 5, No. 6, 59, 28.06.2013.

Research output: Contribution to journalArticle

Mesko, B, Poliska, S, Váncsa, A, Szekanecz, Z, Palatka, K, Hollo, Z, Horvath, A, Steiner, L, Zahuczky, G, Podani, J & Nagy, L 2013, 'Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease', Genome Medicine, vol. 5, no. 6, 59. https://doi.org/10.1186/gm463
Mesko, Bertalan ; Poliska, Szilard ; Váncsa, Andrea ; Szekanecz, Zoltan ; Palatka, Karoly ; Hollo, Zsolt ; Horvath, Attila ; Steiner, Laszlo ; Zahuczky, Gabor ; Podani, Janos ; Nagy, Laszlo. / Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease. In: Genome Medicine. 2013 ; Vol. 5, No. 6.
@article{339f80d8fa894125bc29e0f871c65249,
title = "Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease",
abstract = "Background: Biological therapies have been introduced for the treatment of chronic inflammatory diseases including rheumatoid arthritis (RA) and Crohn's disease (CD). The efficacy of biologics differs from patient to patient. Moreover these therapies are rather expensive, therefore treatment of primary non-responders should be avoided.Method: We addressed this issue by combining gene expression profiling and biostatistical approaches. We performed peripheral blood global gene expression profiling in order to filter the genome for target genes in cohorts of 20 CD and 19 RA patients. Then RT-quantitative PCR validation was performed, followed by multivariate analyses of genes in independent cohorts of 20 CD and 15 RA patients, in order to identify sets ofinterrelated genes that can separate responders from non-responders to the humanized chimeric anti-TNFalpha antibody infliximab at baseline.Results: Gene panels separating responders from non-responders were identified using leave-one-out cross-validation test, and a pool of genes that should be tested on larger cohorts was created in both conditions.Conclusions: Our data show that peripheral blood gene expression profiles are suitable for determining gene panels with high discriminatory power to differentiate responders from non-responders in infliximab therapy at baseline in CD and RA, which could be cross-validated successfully. Biostatistical analysis of peripheral blood gene expression data leads to the identification of gene panels that can help predict responsiveness of therapy and support the clinical decision-making process.",
author = "Bertalan Mesko and Szilard Poliska and Andrea V{\'a}ncsa and Zoltan Szekanecz and Karoly Palatka and Zsolt Hollo and Attila Horvath and Laszlo Steiner and Gabor Zahuczky and Janos Podani and Laszlo Nagy",
year = "2013",
month = "6",
day = "28",
doi = "10.1186/gm463",
language = "English (US)",
volume = "5",
journal = "Genome Medicine",
issn = "1756-994X",
publisher = "BioMed Central",
number = "6",

}

TY - JOUR

T1 - Peripheral blood derived gene panels predict response to infliximab in rheumatoid arthritis and Crohn's disease

AU - Mesko, Bertalan

AU - Poliska, Szilard

AU - Váncsa, Andrea

AU - Szekanecz, Zoltan

AU - Palatka, Karoly

AU - Hollo, Zsolt

AU - Horvath, Attila

AU - Steiner, Laszlo

AU - Zahuczky, Gabor

AU - Podani, Janos

AU - Nagy, Laszlo

PY - 2013/6/28

Y1 - 2013/6/28

N2 - Background: Biological therapies have been introduced for the treatment of chronic inflammatory diseases including rheumatoid arthritis (RA) and Crohn's disease (CD). The efficacy of biologics differs from patient to patient. Moreover these therapies are rather expensive, therefore treatment of primary non-responders should be avoided.Method: We addressed this issue by combining gene expression profiling and biostatistical approaches. We performed peripheral blood global gene expression profiling in order to filter the genome for target genes in cohorts of 20 CD and 19 RA patients. Then RT-quantitative PCR validation was performed, followed by multivariate analyses of genes in independent cohorts of 20 CD and 15 RA patients, in order to identify sets ofinterrelated genes that can separate responders from non-responders to the humanized chimeric anti-TNFalpha antibody infliximab at baseline.Results: Gene panels separating responders from non-responders were identified using leave-one-out cross-validation test, and a pool of genes that should be tested on larger cohorts was created in both conditions.Conclusions: Our data show that peripheral blood gene expression profiles are suitable for determining gene panels with high discriminatory power to differentiate responders from non-responders in infliximab therapy at baseline in CD and RA, which could be cross-validated successfully. Biostatistical analysis of peripheral blood gene expression data leads to the identification of gene panels that can help predict responsiveness of therapy and support the clinical decision-making process.

AB - Background: Biological therapies have been introduced for the treatment of chronic inflammatory diseases including rheumatoid arthritis (RA) and Crohn's disease (CD). The efficacy of biologics differs from patient to patient. Moreover these therapies are rather expensive, therefore treatment of primary non-responders should be avoided.Method: We addressed this issue by combining gene expression profiling and biostatistical approaches. We performed peripheral blood global gene expression profiling in order to filter the genome for target genes in cohorts of 20 CD and 19 RA patients. Then RT-quantitative PCR validation was performed, followed by multivariate analyses of genes in independent cohorts of 20 CD and 15 RA patients, in order to identify sets ofinterrelated genes that can separate responders from non-responders to the humanized chimeric anti-TNFalpha antibody infliximab at baseline.Results: Gene panels separating responders from non-responders were identified using leave-one-out cross-validation test, and a pool of genes that should be tested on larger cohorts was created in both conditions.Conclusions: Our data show that peripheral blood gene expression profiles are suitable for determining gene panels with high discriminatory power to differentiate responders from non-responders in infliximab therapy at baseline in CD and RA, which could be cross-validated successfully. Biostatistical analysis of peripheral blood gene expression data leads to the identification of gene panels that can help predict responsiveness of therapy and support the clinical decision-making process.

UR - http://www.scopus.com/inward/record.url?scp=84879434458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879434458&partnerID=8YFLogxK

U2 - 10.1186/gm463

DO - 10.1186/gm463

M3 - Article

AN - SCOPUS:84879434458

VL - 5

JO - Genome Medicine

JF - Genome Medicine

SN - 1756-994X

IS - 6

M1 - 59

ER -